Myriad Genetics
MYGN
213 hedge funds and large institutions have $2.56B invested in Myriad Genetics in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 77 increasing their positions, 65 reducing their positions, and 13 closing their positions.
108% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 13
77% more call options, than puts
Call options by funds: $7.61M | Put options by funds: $4.29M
18% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 65
11% more capital invested
Capital invested by funds: $2.31B → $2.56B (+$251M)
6% more funds holding
Funds holding: 201 → 213 (+12)
3.57% more ownership
Funds ownership: 97.99% → 101.55% (+3.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$74.3M |
| 2 |
SEI Investments
Oaks,
Pennsylvania
|
+$24.8M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$19.6M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$18M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$10.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$8.52M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$8.3M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$8M |
| 4 |
Millennium Management
New York
|
-$7.77M |
| 5 |
D.E. Shaw & Co
New York
|
-$7.76M |
MYGN Hedge Fund Activity: Q3 2021 in Review
213 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2021, worth a combined $2.56B — up 11% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new MYGN positions and 13 closed out — a net gain of 14 holders — while 77 added to existing stakes and 65 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $74.3M. The largest seller was Two Sigma Advisers, cutting an estimated $8.52M.
- 213 institutional investors held Myriad Genetics (MYGN) as of Q3 2021, up from 201 in Q2 2021.
- Funds reported $2.56B of Myriad Genetics stock for Q3 2021, up 11% quarter-over-quarter.
- 27 funds opened new Myriad Genetics positions in Q3 2021 and 13 closed out, a net change of +14 holders.
- The largest Myriad Genetics buyer in Q3 2021 was Wellington Management Group, an estimated $74.3M added.
- The largest Myriad Genetics seller in Q3 2021 was Two Sigma Advisers, an estimated $8.52M sold.
Based on aggregated 13F filings for Q3 2021.